Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.75

€7.75

-5.280%
-0.432
-5.280%
€13.70
 
12:15 / Tradegate WKN: A2N5Z6 / Symbol: ALT / Name: Altimmune / Stock / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Altimmune Stock

Heavy losses for Altimmune today as the stock fell by -€0.432 (-5.280%).
With 6 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 13 € shows a very positive potential of 67.83% compared to the current price of 7.75 € for Altimmune.
For the coming years our community has positive and negative things to say abot the Altimmune stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.

Pros and Cons of Altimmune in the next few years

Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-25

Upon first glance, the financials of Altimmune, Inc. (ALT) seem to present a mixed picture. The company has managed to maintain a relatively stable asset base over the past few years, but a consistent net loss in its income statements indicates ongoing challenges in operational efficiency. In order to provide a more comprehensive evaluation, this article will delve into the pros and cons of the company's financial performance.

Stable Total Assets: A closer look at the balance sheets reveals that Altimmune's total assets have remained relatively consistent throughout the years, with USD 206.9 million in 2022, USD 218.9 million in 2021, and USD 245.1 million in 2020. This stability suggests that the company is maintaining its asset base and could indicate financial stability.

High Net Working Capital: ALT's net working capital is quite strong, showing a surplus of resources to meet short-term obligations. In 2022, their net working capital was USD 175.8 million, indicating a healthy liquidity position.

Comments

Prediction Buy
Perf. (%) 142.51%
Target price 13.770
Change
Ends at 01.12.24

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 268.72%
Target price 7.497
Change
Ends at 09.11.24

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $15.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 215.19%
Target price 13.722
Change
Ends at 14.08.24

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $50.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Show more

News

Can Altimmune's weight-loss drug be a game-changer?: https://www.marketbeat.com/logos/articles/med_20231210135443_chart-alt.jpg
Can Altimmune's weight-loss drug be a game-changer?

The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold rush for new weight-loss drugs in the medical